GlaxoSmithKline PLC (GSK) Receives News Impact Rating of 0.38

Paterniano Del Favero
Luglio 18, 2017

Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company's stock worth $124,000 after buying an additional 400 shares during the period. GlaxoSmithKline PLC comprises approximately 6.8% of Nexthera Capital LP's holdings, making the stock its 5th largest position.

Among 14 analysts covering GlaxoSmithKline (NYSE:GSK), 7 have Buy rating, 0 Sell and 7 Hold. Jacobs & Co. CA now owns 82,926 shares of the pharmaceutical company's stock valued at $3,575,000 after buying an additional 2,833 shares in the last quarter. Norges Bank purchased a new stake in shares of GlaxoSmithKline PLC during the fourth quarter valued at $19,206,000. Advisory Services Network LLC bought a new stake in shares of GlaxoSmithKline PLC during the first quarter worth about $137,000. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company's stock worth $105,000 after buying an additional 2,359 shares during the period. Finally, Advisors Preferred LLC purchased a new stake in shares of GlaxoSmithKline PLC during the first quarter worth approximately $140,000. Dynamic Advisors Solutions LLC now owns 95,292 shares of the pharmaceutical company's stock valued at $4,017,000 after buying an additional 88,987 shares during the last quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GSK. GlaxoSmithKline plc (ADR) (NYSE:GSK) has risen 4.26% since July 18, 2016 and is uptrending. The stock had a trading volume of 1,227,068 shares. The company has market cap of $101.75 billion. The company's 50 day moving average is $43.56 and its 200-day moving average is $41.27. GlaxoSmithKline PLC has a one year low of $37.20 and a one year high of $45.58.

GlaxoSmithKline PLC (NYSE:GSK) last issued its quarterly earnings data on Wednesday, April 26th. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.62. The business had revenue of $9.23 billion for the quarter, compared to analysts' expectations of $9.09 billion. M&T Bank Corp acquired 232,167 shares as Glaxosmithkline Plc (GSK)'s stock rose 5.47%. On average, equities research analysts forecast that GlaxoSmithKline PLC will post $2.86 EPS for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, July 13th. The firm earned "Buy" rating on Friday, August 12 by Argus Research. The company presently has a consensus rating of "Hold" and an average target price of GBX 1,732.78 ($22.63). This is an increase from GlaxoSmithKline PLC's previous quarterly dividend of $0.46. The ex-dividend date was Thursday, May 11th. GlaxoSmithKline PLC's dividend payout ratio (DPR) is 233.74%.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this report on another website, it was illegally stolen and reposted in violation of United States & worldwide copyright and trademark laws. The legal version of this report can be accessed at https://www.themarketsdaily.com/2017/07/18/glaxosmithkline-plc-longsk-stock-rating-reaffirmed-by-shore-capital.html.

Several research firms have recently commented on GSK. Finally, TheStreet upgraded shares of GlaxoSmithKline PLC from a "c" rating to a "b" rating in a research report on Friday, May 19th. Citigroup Inc. cut shares of GlaxoSmithKline PLC from a "buy" rating to a "neutral" rating in a report on Wednesday, July 5th. Exane BNP Paribas raised shares of GlaxoSmithKline PLC from an "underperform" rating to a "neutral" rating in a report on Wednesday, April 5th. JMP Securities maintained the shares of TRVN in report on Wednesday, September 2 with "Buy" rating. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and ten have issued a buy rating to the company.

GlaxoSmithKline PLC (NYSE:GSK) has earned a consensus recommendation of "Hold" from the twenty-one analysts that are now covering the company, MarketBeat.com reports.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE